<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04998786</url>
  </required_header>
  <id_info>
    <org_study_id>RC21_0169</org_study_id>
    <secondary_id>2021-001587-13</secondary_id>
    <nct_id>NCT04998786</nct_id>
  </id_info>
  <brief_title>A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.&quot;</brief_title>
  <acronym>I2D IFM2021_03</acronym>
  <official_title>A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, multicenter, open-label study to evaluate the rate of patients achieving&#xD;
      very good partial response (VGPR) or better to the oral combination Iberdomide Ixazomib&#xD;
      Dexamethasone in elderly patients with multiple myeloma at first relapse .&#xD;
&#xD;
      The patient population will consist of adult men and women more than 70 years, who meet&#xD;
      eligibility criteria.&#xD;
&#xD;
      Following the screening period, patients will be enrolled and treated then, they will receive&#xD;
      therapy with Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and&#xD;
      Ixazomib until progression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients have very good partial response (VGPR) or better</measure>
    <time_frame>approximate 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>approximate 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responses</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responses</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of the death</measure>
    <time_frame>approximate 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of progression</measure>
    <time_frame>approximate 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time to progression</measure>
    <time_frame>approximative 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of duration of response</measure>
    <time_frame>approximative 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of duration of therapy</measure>
    <time_frame>approximative 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time to response</measure>
    <time_frame>approximative 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Overall Response Rate</measure>
    <time_frame>approximative 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of value of biological prognostic factors</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of frailty scores</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of score of quality of life</measure>
    <time_frame>approximative 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Multiple Myeloma at First Relapse</condition>
  <arm_group>
    <arm_group_label>assessment of treatment Ixazomib, dexamethasone, iberdomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixazomib</intervention_name>
    <description>Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress</description>
    <arm_group_label>assessment of treatment Ixazomib, dexamethasone, iberdomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iberdomide</intervention_name>
    <description>Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress</description>
    <arm_group_label>assessment of treatment Ixazomib, dexamethasone, iberdomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Oral</intervention_name>
    <description>Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22</description>
    <arm_group_label>assessment of treatment Ixazomib, dexamethasone, iberdomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 70 years&#xD;
&#xD;
          2. Eastern Collaborative Oncology Group (ECOG) performance score of ≤2&#xD;
&#xD;
          3. Life expectancy &gt; 6 months&#xD;
&#xD;
          4. Voluntary written informed consent must be given before performance of any&#xD;
             study-related procedure not part of normal medical care, with the understanding that&#xD;
             the subject may withdraw consent at any time without prejudice to future medical care.&#xD;
&#xD;
          5. Symptomatic multiple myeloma (MM) at first relapse, as defined below:&#xD;
&#xD;
               -  Symptomatic multiple myeloma according to international criteria.(Rajkumar et al,&#xD;
                  2014)&#xD;
&#xD;
               -  Relapsed MM is defined as previously treated MM that progresses and requires&#xD;
                  initiation of salvage therapy.&#xD;
&#xD;
          6. Subject must have received one prior line of therapy for at least 3 cycles.&#xD;
&#xD;
          7. Subject has measurable disease at Screening, defined at least one of the following:&#xD;
&#xD;
               -  Serum M-protein ≥ 0.5 gram (g)/deciliter (dL), OR&#xD;
&#xD;
               -  Urine M-protein ≥ 200 mg in 24 hours, OR&#xD;
&#xD;
               -  Serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL provided serum FLC ratio&#xD;
                  is abnormal.&#xD;
&#xD;
          8. Subjects must meet the following laboratory parameters, per laboratory reference range&#xD;
             (performed at most 15 days before cycle 1 day 1):&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1000/microliter (μL). Subjects may use growth&#xD;
                  factor support to achieve ANC eligibility criteria.&#xD;
&#xD;
               -  Platelet count ≥ 75,000 /mm3 for subjects in whom &lt; 50% of bone marrow nucleated&#xD;
                  cells are plasma cells; or a platelet count ≥ 50,000/mm3 for subjects in whom &gt;&#xD;
                  50% of bone marrow nucleated cells are plasma cells. It is not permissible to&#xD;
                  transfuse subjects to achieve minimum platelet counts within 3 days before study.&#xD;
&#xD;
                  --AST and ALT ≤ 3 × upper limit of normal (ULN).&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 × ULN. Subjects with documented Gilbert's syndrome may have&#xD;
                  bilirubin &gt; 1.5 × ULN with the approval of the Primary Therapeutic Area Medical&#xD;
                  Director&#xD;
&#xD;
               -  Creatinine clearance (CrCl) ≥ 30 milliliter (mL)/minute (min) (using Cockroft and&#xD;
                  Gault Formula)&#xD;
&#xD;
          9. Patient should comply with Celgene's pregnancy prevention plan for Iberdomide (please&#xD;
             see appendix 8 Iberdomide Pregnancy Prevention Plan for subjects in clinical trials)&#xD;
&#xD;
         10. Female patients who:&#xD;
&#xD;
               -  are postmenopausal for at least 24 months before the screnning visit, OR&#xD;
&#xD;
               -  are surgically sterile (have undergone a hysterectomy or bilateral oophorectomy)&#xD;
&#xD;
         11. Men even if surgically sterilized must agree to not father a child and agree to&#xD;
             practice complete abstinence or to use a condom during therapy and dose interruptions&#xD;
             and for 90 days after the last dose of study drug, even if they have had a successful&#xD;
             vasectomy, if their partner is of childbearing potential or pregnant.&#xD;
&#xD;
        Non-inclusion Criteria:&#xD;
&#xD;
          1. Subject is refractory to bortezomib, defined as progression on or within 60 days of&#xD;
             the last dose of bortezomib.&#xD;
&#xD;
          2. Subject has had prior treatment with ixazomib, carfilzomib, pomalidomide or iberdomide&#xD;
&#xD;
          3. Subject has any of the following conditions:&#xD;
&#xD;
               -  Non-secretory or oligo-secretory MM&#xD;
&#xD;
               -  Light chain Amyloidosis (AL Amyloidosis)&#xD;
&#xD;
               -  POEMS syndrome Waldenström macroglobulinemia&#xD;
&#xD;
          4. Known Human Immunodeficiency Viral (HIV) infection&#xD;
&#xD;
          5. Active hepatitis B or C infection based on blood screen tests&#xD;
&#xD;
          6. Significant cardiovascular or pericardial disease, including uncontrolled angina,&#xD;
             hypertension, arrhythmia, recent myocardial infarction within 6 months, congestive,&#xD;
             heart failure New York Heart Association (NYHA) Class ≥ 3&#xD;
&#xD;
          7. Major surgery within 4 weeks prior screening&#xD;
&#xD;
          8. Acute infections requiring parenteral therapy (antibiotic, antifungal or antiviral)&#xD;
             within 14 days&#xD;
&#xD;
          9. ≥ Grade 3 Peripheral neuropathy or grade 2 with pain&#xD;
&#xD;
         10. Uncontrolled diabetes or uncontrolled hypertension within 14 days&#xD;
&#xD;
         11. Any other medical condition that, in the opinion of the Investigator, would adversely&#xD;
             affect the subject's participation in the study&#xD;
&#xD;
         12. Subject has a history of other active malignancies, including myelodysplastic syndrome&#xD;
             (MDS), within the past 3 years prior to study entry, with the following exceptions:&#xD;
&#xD;
               -  Adequately treated in situ carcinoma of the cervix uteri or the breast,&#xD;
&#xD;
               -  Basal cell carcinoma of the skin or localized squamous cell carcinoma of the&#xD;
                  skin,&#xD;
&#xD;
               -  Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific&#xD;
                  Antigen (PSA) levels off treatment,&#xD;
&#xD;
               -  Previous malignancy with no evidence of disease confined and surgically resected&#xD;
                  (or treated with other modalities) with curative intent and unlikely to impact&#xD;
                  survival during the duration of the study.&#xD;
&#xD;
         13. Known intolerance to steroid therapy&#xD;
&#xD;
         14. Serious medical or psychiatric illness likely to interfere with participation in study&#xD;
&#xD;
         15. Incidence of gastrointestinal disease that may significantly alter the absorption of&#xD;
             oral drugs&#xD;
&#xD;
         16. Subjects unable or unwilling to undergo antithrombotic prophylactic treatment&#xD;
&#xD;
         17. Person under guardianship, trusteeship or deprived of freedom by a judicial or&#xD;
             administrative decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyrille Touzeau</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>KARLIN</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH de Lyon Sud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MANIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HULIN</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU - Hôpital du Haut Lévêque Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EVEILLARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Brest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FOHRER-SONNTAG</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LELEU</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poitiers University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CAILLOT</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Dijon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MACRO</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Caen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PERROT</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FEUGIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>DECAUX</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU - Hôpital de Pontchaillou Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>TIAB</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD les Oudairies La Roche Sur Yon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MOREAU</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CHALETEIX</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Clermont - Ferrand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ARNULF</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital St Louis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BELHADJ</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Henri Mondor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ARAUJO</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH de la cote Basque Bayonne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ORSINI-PIOCELLE</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR Annecy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>STOPPA</last_name>
    <role>Principal Investigator</role>
    <affiliation>IPC Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>RICHEZ</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital de l'Archet Nice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MOTHY</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital St Antoine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Touzeau</last_name>
    <phone>02.40.08.32.71</phone>
    <email>cyrille.touzeau@chu-nantes.fr</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma, elderly patients, first relapse, previous exposed, High Risk, Ixazomib, Iberdomide, Dexametasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

